6533b85dfe1ef96bd12bf203
RESEARCH PRODUCT
Atypical thrombosis associated with VaxZevria (R) (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres
Anthony BronJoëlle MicallefNathalie MassyThomas GeeraertsThierry VialFrancesco SalvoHugo LaujinMariette BaudSophie LiabeufMarie Blanche Valnet-rabierMarie GirotCéline MounierAntoine El KaddissiAntoine ParienteMehdi BenkebilJustine PerezKamel MasmoudiJean François AlbucherSophie GautierFrançois MontastrucAnnie-pierre Jonville-béraAurélie GrandvuilleminEvelyne MassardierNicolas RaposoCharlène BoulayValérie Gras-champelsubject
2019-20 coronavirus outbreakTime FactorsCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[SDV]Life Sciences [q-bio]Letter to EditorAntiviral AgentsPharmacovigilancePharmacovigilancemedicineAdverse Drug Reaction Reporting SystemsHumansPharmacology (medical)PandemicsComputingMilieux_MISCELLANEOUSCovid-19 vaccineSARS-CoV-2business.industryCOVID-19VaxZevria®medicine.diseaseAtypical thrombosisThrombosisVirology[SDV] Life Sciences [q-bio]Anti-PF4 antibodiesFrancebusinessThrombopeniadescription
The current COVID-19 pandemic is an exceptional health situation including for drug use. As there was no known effective drug for COVID-19 at the beginning of the pandemic, different candidates were proposed. In this short article, we present the French public pharmacovigilance activities during this health crisis. Although COVID-19 is a confounding factor per se, owing to its potential for multi-organ damage including the heart and kidney, the quality of the transmitted data in adverse drug reaction reports, the timeliness of feedback from clinicians, and the real-time pharmacological and medical analysis by the French network of the regional pharmacovigilance centers made it possible to swiftly identify relevant safety signals. The French National Agency of Medicine was thus able to validate the data and convey their findings very early. This decentralized organization based on medical and pharmacological evaluation of case reports has proven to be efficient and responsive in this unique and challenging healthcare emergency.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-01-01 |